tyrosine kinase inhibitor

You have access
Leptomeningeal Metastasis in Patients With EGFR-positive NSCLC: A Propensity-matched Retrospective Study of Patients With EGFR-negative NSCLC
HIROAKI SATOH, KUNIHIKO MIYAZAKI, RYOTA NAKAMURA, AYUMI WATANABE, YOSUKE MAEZAWA, GEN OHARA, NORIHIRO KIKUCHI and TOSHIHIRO SHIOZAWA

Anticancer Research March 2026, 46 (3) 1685-1695; DOI: https://doi.org/10.21873/anticanres.18063
You have access
Antitumor Potential of Epigallocatechin Gallate in Overcoming Molecular Therapy Resistance in Hepatocellular Carcinoma
ATSUO KITAOKA, KYOKO OURA, KOJI FUJITA, KOTA SASAKI, FUMIYUKI SUETSUGU, MAI NAKAHARA, TOMOKO TADOKORO, SHIMA MIMURA, JOJI TANI, ASAHIRO MORISHITA, ERIKA OMAYU, HISAKAZU IWAMA, TSUTOMU MASAKI and HIDEKI KOBARA

Anticancer Research October 2025, 45 (10) 4211-4229; DOI: https://doi.org/10.21873/anticanres.17773
Open Access
Efficacy of Second-line Nivolumab Versus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma With Bone Metastases
GAKU YAMAMICHI, TAIGO KATO, AKIHIRO YOSHIMURA, MASARU TANI, YUKI HORIBE, YUTONG LIU, NESRINE SASSI, YOHEI OKUDA, TOSHIKI OKA, TOSHIHIRO UEMURA, AKINARU YAMAMOTO, YU ISHIZUYA, TAKUJI HAYASHI, YOSHIYUKI YAMAMOTO, KOJI HATANO, ATSUNARI KAWASHIMA, TETSUYA TAKAO, KENSAKU NISHIMURA, SHINGO TAKADA, MASAO TSUJIHATA and NORIO NONOMURA

Anticancer Research February 2025, 45 (2) 639-650; DOI: https://doi.org/10.21873/anticanres.17451
You have access
Treatment Outcomes of Tyrosine Kinase Inhibitors and Durvalumab Plus Tremelimumab After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
NOBUAKI ISHIHARA, SHOHEI KOMATSU, YOSHIHIKO YANO, YOSHIMI FUJISHIMA, JUN ISHIDA, MASAHIRO KIDO, HIDETOSHI GON, KENJI FUKUSHIMA, TAKESHI URADE, TOSHIHIKO YOSHIDA, KENTARO TAI, KEISUKE ARAI, HIROAKI YANAGIMOTO, HIROCHIKA TOYAMA, TAKANORI MATSUURA, TOSHIFUMI TADA, YUZO KODAMA and TAKUMI FUKUMOTO

Anticancer Research January 2025, 45 (1) 251-260; DOI: https://doi.org/10.21873/anticanres.17412
You have access
Comparing Immuno-oncology Combination Therapy With Tyrosine Kinase Inhibitor Monotherapy for Advanced Renal Cell Carcinoma
GAKU ISHIKAWA, KEITA TAMURA, YOSHIHIRO TSUCHIYA, SHUNSUKE WATANABE, TAKEMURA AYANA, SANO ASUKA, KYOHEI WATANABE, HIROMITSU WATANABE, YUTO MATSUSHITA, DAISUKE MOTOYAMA, ATSUSHI OTSUKA and TERUO INAMOTO

Anticancer Research January 2025, 45 (1) 379-386; DOI: https://doi.org/10.21873/anticanres.17426
You have access
Prevalence of PD-L1 in Cervical Cancer Patients and the Potential for Combining an Immune Checkpoint Inhibitor With Lenvatinib
KAREN BRÄUTIGAM, TALINA SCHMIDT, MEIKE BAUR, NIKOLAS TAUBER, EMMANUEL N. KONTOMANOLIS, FRANZISKA HEMPTENMACHER, ACHIM RODY and FRANK KÖSTER

Anticancer Research February 2024, 44 (2) 503-510; DOI: https://doi.org/10.21873/anticanres.16838
Open Access
Lung Cancer – Standard Therapy and the Use of a Novel, Highly Effective, Well Tolerated, Treatment With Progesterone Receptor Modulators
JEROME H. CHECK, TRINA PORETTA, DIANE CHECK and MAYA SRIVASTAVA

Anticancer Research March 2023, 43 (3) 951-965; DOI: https://doi.org/10.21873/anticanres.16240
You have access
Impact of Post-progression Survival on Outcomes of Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Retrospective Cohort Study
KAZUTO TAJIRI, YOSHIHARU TOKIMITSU, KENGO KAWAI, YUCHI MOTOFUJI, EIJI SHINNO, YOSHIRO KASHII, NOZOMU MURAISHI, AIKO MURAYAMA, YUKA HAYASHI, MASAMI MINEMURA, TERUMI TAKAHARA, YUKIHIRO SHIMIZU and ICHIRO YASUDA

Anticancer Research December 2022, 42 (12) 6007-6018; DOI: https://doi.org/10.21873/anticanres.16112
You have access
Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan
NAOTAKA SHIMOZATO, TADASHI NAMISAKI, AKIHIRO OKANO, MASAYA OHANA, DAISUKE KINOSHITA, TOSHIHIKO KAWASAKI, YOSUKE AIHARA, TOSHIYA NAKATANI, HIROKI KINOSHITA, TATSUICHI ANN, KO SAITO, MOTOYUKI YOSHIDA and HITOSHI YOSHIJI

Anticancer Research January 2022, 42 (1) 173-183; DOI: https://doi.org/10.21873/anticanres.15471
You have access
Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma
TAIGO KATO, AKIRA NAGAHARA, NORIHIKO KAWAMURA, WATARU NAKATA, TETSUJI SODA, KYOSUKE MATSUZAKI, KOJI HATANO, ATSUNARI KAWASHIMA, TAKESHI UJIKE, RYOICHI IMAMURA, KENSAKU NISHIMURA, SHINGO TAKADA, MASAO TSUJIHATA, SEIJI YAMAGUCHI, TETSUYA TAKAO, YASUTOMO NAKAI, MASASHI NAKAYAMA, NORIO NONOMURA and MOTOHIDE UEMURA

Anticancer Research November 2021, 41 (11) 5811-5816; DOI: https://doi.org/10.21873/anticanres.15398

Main menu

User menu

Search

tyrosine kinase inhibitor

Pages